Delivering medication in the suprachoroidal space would be less invasive than intravitreal injections used to deliver many eye treatments.
Positive results for suprachoroidal delivery of an Investigational gene therapy for diabetic retinopathy were reported on Friday at the annual meeting of the American Academy of Ophthalmology meeting in San Francisco.
Suber S. Huang, M.D., MBA, of the Retina Center of Ohio in Cleveland and a member of the panel of discussants at the session for late-breaking research, says one of the takeaways from that research is that the suprachoroidal space looks to be promising location for delivering ophthalmic medications.
The suprachoroidal space is a potential space between the sclera, the protective membrane that wraps around most of the eyeball and gives the eyeball its white appearance and choroid, a thin layer of tissue composed mainly of blood vessels that is sandwiched between the sclera and the retina on the back side of the eye.
The study results are “yet another indication that a suprachoroidal approach without the need for vitrectomy or working under the retinal or direct intravitreal injection may be a useful option in our management armamentarium,” said Huang.
High-Dose Eylea Shows Unique Properties in nAMD and DME | AAO 2024
October 22nd 2024A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks to as long as 20 weeks for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Read More
The Link between GLP-1 Drugs and Diabetic Retinopathy Is Not So Clear | AAO 2024
Published: October 21st 2024 | Updated: October 21st 2024Clinical and other trials for GLP-1 therapies have found an association between these drugs and diabetic retinopathy complications in patients. But this could be an early worsening of disease unrelated to treatment.
Read More